Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31
Harrison and colleagues conducted a phase III trial in adults with NASH and fibrosis who received resmetirom once daily at a dose of 80 mg, 100 mg, or placebo for 52 weeks: 25.9% of the patients receiving 80 mg of resmetirom and 29.9% of the patients receiving 100 mg had MASH resolution compared to 9.7% in the placebo group
Furthermore, many of the metabolic improvements, particularly those related to insulin sensitivity and cardiovascular health, persist partially even with some weight regain
This neuroprotection was dose-dependent and mechanistically distinct from IGF-1R-mediated neuroprotection providing the foundational evidence for PEG-MGFs use in CNS neuroprotection research
So much so that I decided to become a partial owner in the company
Personalized Evaluation at Infinite Wellness At Infinite Wellness Hormone Specialists, we take a personalized approach to your weight loss journey
